Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
CSE:ZEAL
Price:
578.5
DKK
-1.2%
Market Closed
Market Cap:
41.1B
DKK
Income Statement
Earnings Waterfall
Zealand Pharma A/S
Zealand Pharma A/S
|
Revenue
|
62.7m
DKK
|
|
Cost of Revenue
|
-7.9m
DKK
|
|
Gross Profit
|
54.8m
DKK
|
|
Operating Expenses
|
-1.3B
DKK
|
|
Operating Income
|
-1.3B
DKK
|
|
Other Expenses
|
190.2m
DKK
|
|
Net Income
|
-1.1B
DKK
|
Income Statement
Zealand Pharma A/S
Zealand Pharma A/S
Currency: DKK
Millions
TTM
| Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||
| Revenue |
154
N/A
|
75
-51%
|
78
+4%
|
27
-66%
|
188
+600%
|
188
+0%
|
189
+0%
|
221
+17%
|
231
+4%
|
301
+30%
|
303
+1%
|
302
0%
|
136
-55%
|
69
-49%
|
74
+7%
|
35
-53%
|
38
+8%
|
28
-26%
|
33
+17%
|
43
+30%
|
41
-4%
|
54
+30%
|
255
+374%
|
301
+18%
|
192
-36%
|
347
+81%
|
162
-53%
|
160
-1%
|
109
-32%
|
119
+10%
|
119
0%
|
109
-9%
|
104
-4%
|
118
+13%
|
92
-22%
|
343
+275%
|
343
0%
|
344
+0%
|
368
+7%
|
77
-79%
|
63
-18%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(28)
|
(62)
|
0
|
(91)
|
(74)
|
(40)
|
(11)
|
(15)
|
(3)
|
(3)
|
0
|
0
|
0
|
(5)
|
(19)
|
(24)
|
(33)
|
(21)
|
(8)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
20
N/A
|
29
+49%
|
41
+39%
|
53
+30%
|
227
+325%
|
239
+6%
|
192
-20%
|
256
+33%
|
88
-66%
|
120
+36%
|
98
-19%
|
105
+7%
|
116
+11%
|
105
-10%
|
104
-1%
|
0
N/A
|
0
N/A
|
315
N/A
|
324
+3%
|
310
-4%
|
335
+8%
|
55
-83%
|
55
-1%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(227)
|
(227)
|
(230)
|
(237)
|
(252)
|
(268)
|
(290)
|
(298)
|
(327)
|
(337)
|
(345)
|
(364)
|
(385)
|
(403)
|
(428)
|
651
|
(501)
|
577
|
551
|
(590)
|
(614)
|
(676)
|
(766)
|
(867)
|
(794)
|
(1 132)
|
(1 201)
|
(1 174)
|
(880)
|
(1 072)
|
(1 226)
|
(1 219)
|
(880)
|
(1 123)
|
(859)
|
(899)
|
(885)
|
(1 115)
|
(1 066)
|
(1 182)
|
(1 324)
|
|
| Selling, General & Administrative |
(40)
|
(39)
|
(41)
|
(45)
|
(37)
|
(42)
|
(46)
|
(39)
|
(44)
|
(46)
|
(39)
|
(44)
|
(47)
|
(38)
|
(40)
|
(43)
|
(40)
|
(50)
|
(62)
|
(68)
|
(65)
|
(71)
|
(171)
|
(293)
|
(212)
|
(595)
|
(641)
|
(576)
|
(294)
|
(392)
|
(371)
|
(358)
|
(264)
|
(310)
|
(214)
|
(202)
|
(190)
|
(235)
|
(266)
|
(311)
|
(395)
|
|
| Research & Development |
(180)
|
(195)
|
(199)
|
(203)
|
(200)
|
(213)
|
(228)
|
(235)
|
(248)
|
(251)
|
(267)
|
(284)
|
(324)
|
(341)
|
(382)
|
(400)
|
(420)
|
(471)
|
(486)
|
(522)
|
(545)
|
(605)
|
(596)
|
(612)
|
(582)
|
(401)
|
(424)
|
(424)
|
(562)
|
(602)
|
(759)
|
(765)
|
(590)
|
(756)
|
(605)
|
(657)
|
(666)
|
(734)
|
(790)
|
(856)
|
(900)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(5)
|
0
|
0
|
0
|
(5)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(25)
|
0
|
0
|
0
|
(27)
|
0
|
0
|
0
|
(28)
|
0
|
0
|
0
|
(29)
|
|
| Other Operating Expenses |
(8)
|
8
|
10
|
11
|
(9)
|
(13)
|
(16)
|
(23)
|
(29)
|
(39)
|
(40)
|
(36)
|
(14)
|
(25)
|
(6)
|
1 095
|
(37)
|
1 098
|
1 100
|
1
|
0
|
0
|
1
|
38
|
0
|
(136)
|
(137)
|
(174)
|
1
|
(78)
|
(96)
|
(96)
|
1
|
(58)
|
(40)
|
(40)
|
0
|
(147)
|
(11)
|
(14)
|
0
|
|
| Operating Income |
(74)
N/A
|
(152)
-107%
|
(152)
+0%
|
(210)
-38%
|
(64)
+69%
|
(80)
-24%
|
(101)
-27%
|
(76)
+25%
|
(96)
-26%
|
(36)
+63%
|
(42)
-18%
|
(61)
-45%
|
(249)
-305%
|
(334)
-34%
|
(353)
-6%
|
687
N/A
|
(463)
N/A
|
605
N/A
|
584
-4%
|
(547)
N/A
|
(573)
-5%
|
(622)
-9%
|
(540)
+13%
|
(628)
-16%
|
(602)
+4%
|
(876)
-45%
|
(1 113)
-27%
|
(1 054)
+5%
|
(782)
+26%
|
(967)
-24%
|
(1 110)
-15%
|
(1 114)
0%
|
(776)
+30%
|
(1 006)
-30%
|
(767)
+24%
|
(560)
+27%
|
(561)
0%
|
(795)
-42%
|
(732)
+8%
|
(1 126)
-54%
|
(1 269)
-13%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
1
|
(4)
|
(36)
|
(44)
|
(45)
|
(60)
|
(58)
|
(64)
|
(66)
|
(77)
|
(67)
|
(60)
|
(31)
|
(17)
|
(14)
|
(33)
|
(43)
|
(10)
|
(16)
|
26
|
(6)
|
0
|
(3)
|
(28)
|
(67)
|
(24)
|
(32)
|
(8)
|
19
|
142
|
168
|
161
|
(15)
|
(98)
|
(100)
|
(81)
|
19
|
55
|
65
|
119
|
196
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1 133
|
0
|
0
|
0
|
0
|
(7)
|
(7)
|
(7)
|
0
|
0
|
0
|
0
|
(2)
|
0
|
(145)
|
(145)
|
(184)
|
9
|
18
|
18
|
(147)
|
0
|
0
|
0
|
(3)
|
|
| Total Other Income |
0
|
0
|
0
|
(1)
|
(10)
|
(4)
|
(4)
|
(3)
|
(0)
|
(1)
|
(1)
|
(1)
|
0
|
(1)
|
(1)
|
0
|
(2)
|
0
|
0
|
(1)
|
3
|
0
|
0
|
0
|
(5)
|
0
|
(1)
|
1
|
7
|
(3)
|
68
|
68
|
3
|
(73)
|
(144)
|
(144)
|
(20)
|
(3)
|
(50)
|
(50)
|
(7)
|
|
| Pre-Tax Income |
(72)
N/A
|
(156)
-115%
|
(188)
-21%
|
(256)
-36%
|
(120)
+53%
|
(144)
-20%
|
(163)
-14%
|
(143)
+13%
|
(163)
-14%
|
(112)
+31%
|
(109)
+3%
|
(122)
-12%
|
(280)
-130%
|
(351)
-25%
|
(367)
-5%
|
653
N/A
|
625
-4%
|
595
-5%
|
568
-4%
|
(522)
N/A
|
(577)
-10%
|
(628)
-9%
|
(549)
+13%
|
(663)
-21%
|
(674)
-2%
|
(901)
-34%
|
(1 146)
-27%
|
(1 061)
+7%
|
(759)
+28%
|
(828)
-9%
|
(1 019)
-23%
|
(1 030)
-1%
|
(972)
+6%
|
(1 167)
-20%
|
(992)
+15%
|
(766)
+23%
|
(709)
+7%
|
(744)
-5%
|
(717)
+4%
|
(1 057)
-48%
|
(1 083)
-2%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
8
|
9
|
10
|
10
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
7
|
6
|
6
|
6
|
(52)
|
(44)
|
(44)
|
(44)
|
14
|
5
|
5
|
5
|
3
|
5
|
(9)
|
(3)
|
(1)
|
4
|
(2)
|
(7)
|
(6)
|
6
|
8
|
6
|
6
|
5
|
5
|
5
|
5
|
5
|
|
| Income from Continuing Operations |
(65)
|
(147)
|
(178)
|
(246)
|
(114)
|
(138)
|
(157)
|
(137)
|
(157)
|
(107)
|
(103)
|
(115)
|
(274)
|
(346)
|
(362)
|
601
|
581
|
551
|
524
|
(508)
|
(572)
|
(623)
|
(545)
|
(660)
|
(669)
|
(909)
|
(1 149)
|
(1 062)
|
(755)
|
(831)
|
(1 026)
|
(1 036)
|
(966)
|
(1 159)
|
(986)
|
(760)
|
(704)
|
(739)
|
(712)
|
(1 053)
|
(1 079)
|
|
| Net Income (Common) |
(65)
N/A
|
(147)
-127%
|
(178)
-21%
|
(246)
-38%
|
(114)
+54%
|
(138)
-21%
|
(157)
-14%
|
(137)
+13%
|
(157)
-15%
|
(107)
+32%
|
(103)
+3%
|
(115)
-12%
|
(274)
-138%
|
(346)
-26%
|
(362)
-5%
|
601
N/A
|
581
-3%
|
551
-5%
|
524
-5%
|
(508)
N/A
|
(572)
-12%
|
(623)
-9%
|
(545)
+13%
|
(660)
-21%
|
(847)
-28%
|
(909)
-7%
|
(1 148)
-26%
|
(1 118)
+3%
|
(1 018)
+9%
|
(999)
+2%
|
(1 413)
-42%
|
(1 363)
+4%
|
(1 202)
+12%
|
(1 396)
-16%
|
(1 004)
+28%
|
(781)
+22%
|
(704)
+10%
|
(739)
-5%
|
(712)
+4%
|
(1 053)
-48%
|
(1 079)
-2%
|
|
| EPS (Diluted) |
-2.85
N/A
|
-6.41
-125%
|
-7.69
-20%
|
-10.63
-38%
|
-4.82
+55%
|
-5.75
-19%
|
-6.56
-14%
|
-5.7
+13%
|
-6.47
-14%
|
-4.16
+36%
|
-4.02
+3%
|
-4.04
0%
|
-9.85
-144%
|
-11.25
-14%
|
-11.77
-5%
|
19.53
N/A
|
18.94
-3%
|
17.86
-6%
|
16.56
-7%
|
-15.45
N/A
|
-16.91
-9%
|
-16.9
+0%
|
-14.65
+13%
|
-16.62
-13%
|
-22.06
-33%
|
-21.68
+2%
|
-26.57
-23%
|
-25.91
+2%
|
-23.75
+8%
|
-23.11
+3%
|
-31.1
-35%
|
-29.44
+5%
|
-26.02
+12%
|
-27.1
-4%
|
-17.28
+36%
|
-12.96
+25%
|
-12.44
+4%
|
-11.98
+4%
|
-11.35
+5%
|
-14.89
-31%
|
-16.24
-9%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
